Table 2.
Selected clinical trials with cytokine/chemokine genetically-modified CAR T cells.
| Clinical trial ID | Status | Cytokine/Chemokine Genetic Modification | CAR | Condition or disease | Phase |
|---|---|---|---|---|---|
| NCT04099797 | Recruiting | C7R1 | GD2-CAR | High Grade Glioma/Diffuse Intrinsic Pontine Glioma/Medulloblastoma | Phase 1 |
| NCT03635632 | Recruiting | C7R | GD2-CAR | Relapsed/Refractory Neuroblastoma | Phase 1 |
| NCT03198546 | Recruiting | IL-7 and CCL19 | GPC3-CAR | Hepatocellular Carcinoma or Squamous Cell Lung Cancer | Phase 1 |
| NCT03929107 | Recruiting | IL-7 and CCL19 | CD19-CAR | Refractory/Relapsed B Cell Lymphoma | Phase 2 |
| NCT04381741 | Recruiting | IL-7 and CCL19 | CD19-CAR | Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 1 |
| NCT03778346 | Recruiting | IL-7 and CCL19 | BCMA-CAR, CD138-CAR, CD38-CAR, Integrin β7-CAR, CS1-CAR | Relapsed/Refractory Multiple Myeloma | Phase 1 |
| NCT03932565 | Recruiting | IL-7 and CCL19, or IL-12 | Nectin4/FAP-CAR | Solid Tumors | Phase 1 |
| NCT03721068 | Recruiting | IL-15 | GD2-CAR | Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | Phase 1 |
| NCT04377932 | Recruiting | IL-15 | GPC3-CAR | Pediatric Solid Tumors | Phase 1 |
| NCT03579888 | Terminated | mbIL-152 | CD19-CAR | B Cell Lymphoma and Leukemia | Phase 1 |
| NCT04715191 | Not yet recruiting | IL-15 and IL-21 | GPC3-CAR | Pediatric Solid Tumors | Phase 1 |
| NCT02498912 | Active, not recruiting | IL-12 | 4H11-CAR | MUC16ecto+ Solid Tumors | Phase 1 |
| NCT03542799 | Unknown | IL-12 | EGFR-CAR | Metastatic Colorectal Cancer | Phase 1 and 2 |
| NCT01818323 | Recruiting | IL-4Rα and IL-2Rβ (4αβ) | T1E-CAR | Head and Neck Squamous Cell Carcinoma | Phase 1 |
| NCT04153799 | Recruiting | CXCR5 | EGFR-CAR | Non-Small Cell Lung Cancer | Phase 1 |